vs
KFORCE INC（KFRC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
KFORCE INC的季度营收约是Orthofix Medical Inc.的1.5倍（$330.4M vs $219.9M），KFORCE INC净利率更高（2.4% vs -1.0%，领先3.4%），Orthofix Medical Inc.同比增速更快（2.0% vs 0.1%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-7.4M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -3.7%）
Kforce Inc.是一家总部位于美国的专业人力资源服务与解决方案供应商，业务覆盖技术、财务会计、医疗保健三大核心领域，为全美各类中大型企业提供专业人才派遣、劳动力管理优化等定制服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
KFRC vs OFIX — 直观对比
营收规模更大
KFRC
是对方的1.5倍
$219.9M
营收增速更快
OFIX
高出1.9%
0.1%
净利率更高
KFRC
高出3.4%
-1.0%
自由现金流更多
OFIX
多$24.2M
$-7.4M
两年增速更快
OFIX
近两年复合增速
-3.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $330.4M | $219.9M |
| 净利润 | $7.9M | $-2.2M |
| 毛利率 | 27.3% | 71.1% |
| 营业利润率 | 3.6% | 0.2% |
| 净利率 | 2.4% | -1.0% |
| 营收同比 | 0.1% | 2.0% |
| 净利润同比 | -2.7% | 92.4% |
| 每股收益（稀释后） | $0.46 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KFRCOFIX
| Q1 26 | $330.4M | — | ||
| Q4 25 | $332.0M | $219.9M | ||
| Q3 25 | $332.6M | $205.6M | ||
| Q2 25 | $334.3M | $203.1M | ||
| Q1 25 | $330.0M | $193.6M | ||
| Q4 24 | $343.8M | $215.7M | ||
| Q3 24 | $353.3M | $196.6M | ||
| Q2 24 | $356.3M | $198.6M |
净利润KFRCOFIX
| Q1 26 | $7.9M | — | ||
| Q4 25 | $5.2M | $-2.2M | ||
| Q3 25 | $11.1M | $-22.8M | ||
| Q2 25 | $10.4M | $-14.1M | ||
| Q1 25 | $8.1M | $-53.1M | ||
| Q4 24 | $11.1M | $-29.1M | ||
| Q3 24 | $14.2M | $-27.4M | ||
| Q2 24 | $14.2M | $-33.4M |
毛利率KFRCOFIX
| Q1 26 | 27.3% | — | ||
| Q4 25 | 27.2% | 71.1% | ||
| Q3 25 | 27.7% | 72.2% | ||
| Q2 25 | 27.1% | 68.7% | ||
| Q1 25 | 26.7% | 62.8% | ||
| Q4 24 | 27.0% | 69.0% | ||
| Q3 24 | 27.9% | 68.7% | ||
| Q2 24 | 27.8% | 67.8% |
营业利润率KFRCOFIX
| Q1 26 | 3.6% | — | ||
| Q4 25 | 2.6% | 0.2% | ||
| Q3 25 | 4.5% | -8.3% | ||
| Q2 25 | 4.5% | -7.9% | ||
| Q1 25 | 3.5% | -25.2% | ||
| Q4 24 | 4.5% | -5.3% | ||
| Q3 24 | 5.3% | -9.6% | ||
| Q2 24 | 5.5% | -12.5% |
净利率KFRCOFIX
| Q1 26 | 2.4% | — | ||
| Q4 25 | 1.6% | -1.0% | ||
| Q3 25 | 3.3% | -11.1% | ||
| Q2 25 | 3.1% | -6.9% | ||
| Q1 25 | 2.5% | -27.4% | ||
| Q4 24 | 3.2% | -13.5% | ||
| Q3 24 | 4.0% | -13.9% | ||
| Q2 24 | 4.0% | -16.8% |
每股收益（稀释后）KFRCOFIX
| Q1 26 | $0.46 | — | ||
| Q4 25 | $0.29 | $-0.05 | ||
| Q3 25 | $0.63 | $-0.57 | ||
| Q2 25 | $0.59 | $-0.36 | ||
| Q1 25 | $0.45 | $-1.35 | ||
| Q4 24 | $0.60 | $-0.76 | ||
| Q3 24 | $0.75 | $-0.71 | ||
| Q2 24 | $0.75 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $117.4M | $450.0M |
| 总资产 | $384.8M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KFRCOFIX
| Q1 26 | $1.3M | — | ||
| Q4 25 | $2.1M | $82.0M | ||
| Q3 25 | $1.3M | $62.9M | ||
| Q2 25 | $2.5M | $65.6M | ||
| Q1 25 | $444.0K | $58.0M | ||
| Q4 24 | $349.0K | $83.2M | ||
| Q3 24 | $127.0K | $30.1M | ||
| Q2 24 | $110.0K | $26.4M |
总债务KFRCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益KFRCOFIX
| Q1 26 | $117.4M | — | ||
| Q4 25 | $124.6M | $450.0M | ||
| Q3 25 | $132.1M | $442.5M | ||
| Q2 25 | $134.4M | $458.3M | ||
| Q1 25 | $138.0M | $458.3M | ||
| Q4 24 | $154.6M | $503.1M | ||
| Q3 24 | $167.4M | $525.9M | ||
| Q2 24 | $166.6M | $546.0M |
总资产KFRCOFIX
| Q1 26 | $384.8M | — | ||
| Q4 25 | $365.6M | $850.6M | ||
| Q3 25 | $374.2M | $832.6M | ||
| Q2 25 | $373.6M | $837.2M | ||
| Q1 25 | $368.2M | $823.1M | ||
| Q4 24 | $357.8M | $893.3M | ||
| Q3 24 | $369.9M | $867.9M | ||
| Q2 24 | $362.7M | $882.0M |
负债/权益比KFRCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-7.4M | $16.8M |
| 自由现金流率自由现金流/营收 | -2.2% | 7.6% |
| 资本支出强度资本支出/营收 | 1.0% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.3M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流KFRCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $19.7M | $27.7M | ||
| Q3 25 | $23.3M | $12.4M | ||
| Q2 25 | $18.4M | $11.6M | ||
| Q1 25 | $249.0K | $-18.4M | ||
| Q4 24 | $21.8M | $23.7M | ||
| Q3 24 | $31.0M | $11.7M | ||
| Q2 24 | $20.9M | $9.0M |
自由现金流KFRCOFIX
| Q1 26 | $-7.4M | — | ||
| Q4 25 | $16.7M | $16.8M | ||
| Q3 25 | $19.8M | $2.5M | ||
| Q2 25 | $14.2M | $4.5M | ||
| Q1 25 | $-3.9M | $-25.1M | ||
| Q4 24 | $20.9M | $15.2M | ||
| Q3 24 | $27.5M | $6.3M | ||
| Q2 24 | $17.8M | $-360.0K |
自由现金流率KFRCOFIX
| Q1 26 | -2.2% | — | ||
| Q4 25 | 5.0% | 7.6% | ||
| Q3 25 | 6.0% | 1.2% | ||
| Q2 25 | 4.3% | 2.2% | ||
| Q1 25 | -1.2% | -13.0% | ||
| Q4 24 | 6.1% | 7.0% | ||
| Q3 24 | 7.8% | 3.2% | ||
| Q2 24 | 5.0% | -0.2% |
资本支出强度KFRCOFIX
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | 4.9% | ||
| Q3 25 | 1.1% | 4.8% | ||
| Q2 25 | 1.2% | 3.5% | ||
| Q1 25 | 1.3% | 3.5% | ||
| Q4 24 | 0.3% | 4.0% | ||
| Q3 24 | 1.0% | 2.7% | ||
| Q2 24 | 0.9% | 4.7% |
现金转化率KFRCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | — | ||
| Q3 25 | 2.11× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 1.97× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 1.48× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KFRC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
